Indoco Remedies surged 5.05% to Rs 157 after the company said it received establishment inspection report for its manufacturing facilities in Goa.
The company announced before market hours on Monday, 25 November 2019, that it has received an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for its sterile facility (plant II) and solid dosages facility (plant III) at Goa. The inspection was carried out between 7th and 15th October 2019. This was a pre-approval inspection for a sterile injectable product, with 2 observations on Form 483s, which is now concluded as closed. The inspection classification of this site has been determined as VAI (Voluntary Action Indicated) by the USFDA.
Meanwhile, the NSE Nifty 50 index was trading 0.25% higher at 11,943.65.
Indoco Remedies is a fully integrated, research-oriented pharmaceutical company with presence in 55 countries.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app